Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation

Blood

Volumn 107, Issue 4, 2006, Pages 1332-1341

  Rousseau, Raphaël F ^a   Biagi, Ettore ^b   Dutour, Aurélie ^b   Yvon, Eric S ^b   Brown, Michael P ^b   Lin, Tiffany ^b   Mei, Zhuyong ^b   Grilley, Bambi ^b   Popek, Edwina ^b   Heslop, Helen E ^b   Gee, Adrian P ^b   Krance, Robert A ^b   Popat, Uday ^b   Carrum, George ^b   Margolin, Judith F ^b   Brenner, Malcolm K ^b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIINFECTIVE AGENT; CD40 LIGAND; GAMMA INTERFERON; GRANZYME B; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 5; TUMOR VACCINE;

ABSENCE OF SIDE EFFECTS; ACUTE LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; CANCER CHEMOTHERAPY; CANCER RISK; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ERYTHEMA; FEASIBILITY STUDY; FEMALE; HELPER CELL; HISTOCOMPATIBILITY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEUKOCYTOSIS; LYMPHATIC LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MYELOID LEUKEMIA; PATIENT; PRIORITY JOURNAL; RECIPIENT; SAFETY; SKIN ABSCESS; SKIN FIBROBLAST; SKIN INFLAMMATION; SURVIVAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

EID: 32644436462     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-1259     Document Type: Article

References (65)

1. Qazilbash M, Wieder E, Rios R, et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia [abstract]. Blood. 2004;104:259a.
2. Schwartz R. Costimulation of T lymphocytes: the role of CD28, CTLA-4 and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992;71:1065-1068.
3. Townsend S, Allison J. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
4. Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996;88:41-48.
5. Ranheim E, Kipps T. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependant signal. J Exp Med. 1993;177:925-935.
6. Schultze JL, Cardoso AA, Freeman GJ, et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A. 1995;92:8200-8204.
7. Vyth-Dreese F, Dellemijn T, van Oostveen J, Feltkamp C, Hekman A. Functional expression of adhesion receptors and costimulatory molecules by fresh and immortalized B-cell non-Hodgkin's lymphoma cells. Blood. 1995;85:2802-2812.
8. Renard N, Lafage-Pochitaloff M, Durand I, et al. Demonstration of functional CD40 in B-lineage acute lymphoblastic leukemia cells in response to T-cell CD40 ligand. Blood. 1996;87:5162-5170.
9. Ghia P, Transidico P, Veiga JP, et al. Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood. 2001;98:533-540.
10. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180:1263-1272.
11. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
12. Cardoso AA, Seamon MJ, Afonso HM, et al. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood. 1997;90:549-561.
13. Takahashi S, Yotnda P, Rousseau RF, et al. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther. 2001;8:378-387.
14. Takahashi S, Rousseau RF, Yotnda P, et al. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001;12:659-670.
15. von Bergwelt Baildon MS, Vonderheide RH, Maecker B, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood. 2002;99:3319-3325.
16. Biagi E, Yvon E, Dotti G, et al. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther. 2003;14:545-559.
17. Matulonis UA, Dosiou C, Lamont C, et al. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 1995;85:2507-2515.
18. Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, et al. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood. 1996;87:2938-2946.
19. Boyer MW, Vallera DA, Taylor PA, et al. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. Blood. 1997;89:3477-3485.
20. Freudenthal P, Steinman R. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci U S A. 1990;87:7698-7702.
21. Armitage R, Tough T, Macduff B, Fanslow W, Spriggs M, Ramsdell F. CD40 ligand is a T cell growth factor. Eur J Immunol. 1993;23:2326-2331.
22. Cayabyab M, Phillips JH, Lanier LL. CD40 preferentially costimulates activation of CD4+ T lymphocytes. J Immunol. 1994;152:1523-1531.
23. Wagner D, Stout R, Suttles J. Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur J Immunol. 1994;24:3148-3154.
24. Fanslow W, Clifford KN, Seaman M, et al. Recombinant CD40 ligand exerts potent biologic effects on T cells. J Immunol. 1994;152:4262-4269.
25. Paul W, Seder R. Lymphocyte responses and cytokines. Cell. 1994;76:241-251.
26. Carbone E, Ruggiero G, Terrazzano G, et al. A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J Exp Med. 1997;185:2053-2060.
27. Dilloo D, Brown M, Roskrow M, et al. CD40 ligand induces an antileukemia immune response in vivo. Blood. 1997;90:1927-1933.
28. Briones J, Timmerman J, Levy R. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res. 2002;62:3195-3199.
29. Roskrow MA, Dilloo D, Suzuki N, Zhong W, Rooney CM, Brenner MK. Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res. 1999;23:549-557.
30. Gauchat JF, Aubry JP, Mazzei G, et al. Human CD40-ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production. FEBS Lett. 1993;315:259-266.
31. Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998;92:1941-1949.
32. WHO Handbook for Reporting Results for Cancer Treatment. Geneva, Switzerland: WHO Offset Publication No. 48; 1979.
33. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003;101:1718-1726.
34. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990;60:397-403.
35. Cignetti A, Guarini A, Carbone A, et al. Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. J Natl Cancer Inst. 1994;86:785-791.
36. Foa R, Caretto P, Fierro M, et al. Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. Br J Haematol. 1990;75:34-40.
37. Armitage RJ, Maliszewski CR, Alderson MR, Grabstein KH, Spriggs MK, Fanslow WC. CD40L: a multi-functional ligand. Semin Immunol. 1993;5:401-412.
38. Granucci F, Zanoni I, Feau S, Ricciardi-Castagnoli P. Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. EMBO J. 2003;22:2546-2551.
39. Rosolen A, Nakanishi M, Poplack D, et al. Expression of interleukin-2 receptor B subunit in hematopoietic malignancies. Blood. 1989;73:1968-1972.
40. O'Brien D, Boughton B. High and low affinity IL-2 receptors on human leukaemic blast cells. Br J Haematol. 1990;76:315-317.
41. Dilloo D, Hanenberg H, Lion T, Burdach S. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein. Leukemia. 1995;9:419-424.
42. Blanchard D, Gaillard C, Hermann P, Banchereau J. Role of CD40 antigen and interleukin-2 in T cell-dependent human B lymphocyte growth. Eur J Immunol. 1994;24:330-335.
43. Todisco E, Gaipa G, Biagi E, et al. CD40 ligandstimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia. Leukemia. 2002;16:2046-2054.
44. Teichmann JV, Ludwig WD, Thiel E. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples. Nat Immunol. 1992;11:117-132.
45. Mutis T, Goulmy E. Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies. Semin Hematol. 2002;39:23-31.
46. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
47. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998;188:2357-2368.
48. Martin T, Duffy S, Carson D, Kipps T. Evidence for somatic selection of natural autoantibodies. J Exp Med. 1992;175:983-991.
49. Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med. 1999;5:774-779.
50. Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med. 1999;5:780-787.
51. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999;5:548-553.
52. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997;100:2757-2765.
53. Stripecke R, Levine AM, Pullarkat V, Cardoso AA. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia. 2002;16:1974-1983.
54. Hoffmann TK, Meidenbauer N, Muller-Berghaus J, Storkus WJ, Whiteside TL. Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother. 2001;24:162-171.
55. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 2000;60:3542-3549.
56. Maass G, Schmidt W, Berger M, et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci U S A. 1995;92:5540-5544.
57. Moodycliffe AM, Shreedhar V, Ullrich SE, et al. CD40-CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes. J Exp Med. 2000;191:2011-2020.
58. Biagi E, Bambacioni F, Gaipa G, et al. Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells. Haematologica. 2001;86:13-16.
59. Li L, Biagi E, Weiss J, et al. Efficient non-viral transfection of CLL-B cells with human CD40 ligand. Mol Ther. 2002;5:A354.
60. Haining WN, Cardoso AA, Keczkemethy HL, et al. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005;33:286-294.
61. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018-1023.
62. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999;59:2675-2681.
63. Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol. 2002;12:43-50.
64. Wierda W, Cantwell M, Woods S, Rassenti L, Prussak C, Kipps T. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96:2917-2924.
65. Haining WN, Neuberg DS, Keczkemethy HL, et al. Antigen-specific T cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood. 2005;106:1749-1754.